

**ILF/CIPHER Thematic Roundtable on Paediatric ARVs:
Aligning, coordinating and accelerating actions to provide better ARVs for children**

Wednesday, 18 March 2015, 13:00 – 17:00 CET
Geneva, Switzerland

CONCEPT NOTE

Dear colleague

The Industry Liaison Forum ([ILF](#)) Thematic Roundtable Series aims to convene scientific and technical experts from industry and non-industry organizations to discuss topics relevant to IAS member priorities (paediatric HIV, key populations, HIV cure and HIV co-infections) where a multi-stakeholder approach can lead to novel solutions.

The first of the series, on paediatric ARVs (see [meeting report](#)), took place in November 2013 and identified challenges and barriers to industry in making optimal paediatric ARVs available at different levels: research and development, normative guideline formulation, regulatory approval, production, forecasting and supply chain. Specifically, this meeting identified a need for industry to be more informed of the guideline development process, so that changes and new recommendations do not come as a surprise or are not unfeasible from the industry perspective.

At AIDS 2014 (July 2014), investigators from the IAS Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration and regulatory authorities were invited to join the discussion in a follow-up roundtable that focused on exploring collaborative solutions to some of the identified research and development and regulatory challenges (see [meeting report](#)). The meeting highlighted the common goal shared by stakeholders: contributing collaboratively to the development and distribution of better antiretroviral regimens to more infants, children and adolescents. Challenges and opportunities were emphasized, as well as several avenues for follow up, including some specifically through the CIPHER Cohort Collaboration.

The ILF and CIPHER are pleased to hold the third roundtable in this series on Wednesday, 18 March 2015. This meeting will provide an in-depth report back and occasion for discussion and feedback on the December 2014 Paediatric ARV Drug Optimization 2 (PADO2) meeting working-up to the next WHO Consolidated ARV Guideline revision. The group will also have the opportunity for more in-depth discussion on the work being done in the paediatric space on optimal drug formulation (Paediatric HIV Treatment Initiative), coordinated procurement and global supply of paediatric ARVs, and efforts towards alignment of regulatory requirements. The aim is to provide a forum for discussion and feedback to enhance stakeholder effectiveness and synergy.

Thank you for your participation.
Best wishes

Sébastien Morin
*Research Officer, Industry Liaison Forum
International AIDS Society, Switzerland*

Marissa Vicari
*Manager, CIPHER
International AIDS Society, Switzerland*

About the Collaborative Initiative for Paediatric HIV Education and Research

CIPHER is aimed at optimizing clinical management and delivery of services to infants, children and adolescents affected by HIV in resource-limited settings through advocacy and research promotion. CIPHER was launched as a two-year research initiative in 2012 with the generous support of an unrestricted grant from ViiV Healthcare's Paediatric Innovation Seed Fund. Over the first two years, a core programme of activities was developed, including a grant programme, a global paediatric HIV cohort collaboration and online paediatric HIV cohort database. By the end of 2013, the IAS reaffirmed its commitment to paediatric HIV by making paediatrics a programme priority, with CIPHER as the official branding. Thanks to renewed support from founding sponsor ViiV Healthcare and now with support from Janssen as well, CIPHER will continue to build on the activities developed in the initial phase and expand its scope with an advocacy and outreach component. More information is available on the [CIPHER website](#).

About the Industry Liaison Forum

The ILF is a mechanism to inform and support collaboration and partnership between industry and the IAS. It performs this broad task by providing opportunities for industry to understand the IAS's values, interests and priorities, and vice versa, seeking common ground to enhance the impact of the global response to HIV and related co-morbidities. The ILF aims to promote constructive interactions among all stakeholders, including industry, and convene experts from industry and non-industry organizations to discuss topics relevant to IAS member priorities. The ILF is designed to take advantage of the IAS's key strengths: its well-respected convening power; its acknowledged independence towards industry and other key partners and stakeholders; and its diverse working groups composed of some of the world's top thought leaders and scientific experts in a wide array of fields. More information is available on the [ILF website](#).

The ILF is grateful for the unrestricted support received from its Gold Partners (Gilead Sciences, MSD and ViiV Healthcare), its Silver Partners (AbbVie, Alere and Janssen) and its Bronze Partners (Abbott, Female Health Company, Omega Diagnostics, Roche Molecular Systems and Sysmex Corporation). This ILF Thematic Roundtable is a discussion convened by the ILF and sponsored by ILF Gold and Silver Partners.